Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $44.67.
Several equities research analysts have recently weighed in on the company. Northland Securities raised their price objective on Trupanion from $45.00 to $50.00 and gave the stock a “market perform” rating in a research note on Thursday, October 31st. Piper Sandler lifted their price target on Trupanion from $45.00 to $57.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Stifel Nicolaus upped their price objective on shares of Trupanion from $30.00 to $40.00 and gave the company a “hold” rating in a research note on Monday, September 23rd. Bank of America lifted their target price on shares of Trupanion from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Finally, Evercore ISI upgraded shares of Trupanion to a “strong-buy” rating in a research report on Friday, August 9th.
Check Out Our Latest Analysis on TRUP
Trupanion Trading Down 3.9 %
Trupanion (NASDAQ:TRUP – Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The financial services provider reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.09. Trupanion had a negative net margin of 1.08% and a negative return on equity of 4.36%. The company had revenue of $327.50 million during the quarter, compared to analyst estimates of $321.79 million. During the same quarter last year, the firm posted ($0.10) EPS. The business’s revenue for the quarter was up 14.6% on a year-over-year basis. On average, equities analysts forecast that Trupanion will post -0.23 EPS for the current fiscal year.
Insider Transactions at Trupanion
In other news, CEO Margaret Tooth sold 7,500 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $46.48, for a total value of $348,600.00. Following the transaction, the chief executive officer now directly owns 99,984 shares of the company’s stock, valued at approximately $4,647,256.32. This represents a 6.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Murray B. Low sold 2,000 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.67, for a total value of $105,340.00. Following the sale, the director now owns 131,513 shares of the company’s stock, valued at approximately $6,926,789.71. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,124 shares of company stock valued at $482,981 over the last three months. 5.50% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in shares of Trupanion during the 3rd quarter valued at about $37,000. GAMMA Investing LLC raised its position in Trupanion by 70.4% during the third quarter. GAMMA Investing LLC now owns 1,442 shares of the financial services provider’s stock valued at $61,000 after acquiring an additional 596 shares in the last quarter. Entropy Technologies LP acquired a new stake in Trupanion in the third quarter valued at approximately $202,000. Mutual of America Capital Management LLC bought a new stake in Trupanion in the third quarter worth approximately $210,000. Finally, Headlands Technologies LLC acquired a new position in shares of Trupanion during the 2nd quarter worth $162,000.
About Trupanion
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
Featured Stories
- Five stocks we like better than Trupanion
- Ride Out The Recession With These Dividend KingsĀ
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Applied Materials Market Capitulates: Now is the Time to Buy
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.